SCHEMBL3237296

SCHEMBL3237296

FN(C=S)Cc1ccccc1

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.44
TSHR P16473 2/20 0.44
AOC3 Q16853 1/20 0.41
MGLL Q99685 3/20 0.41
G6PC1 P35575 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
CA2 P00918 2/20 0.38
CA12 O43570 1/20 0.38
CA1 P00915 1/20 0.38
CA9 Q16790 1/20 0.38
GAA P10253 1/20 0.38
KDM4E B2RXH2 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
MAOB P27338 1/20 0.37
CARM1 Q86X55 1/20 0.36
PRMT6 Q96LA8 1/20 0.36
PRMT8 Q9NR22 1/20 0.36
CYP2C19 P33261 1/20 0.36
CALM1 P0DP23 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5635827 0.77 ALDH1A1 (0.44) ALDH1A1TSHRAOC3MGLLG6PC1
SCHEMBL81124 0.77 ALDH1A1 (0.44) ALDH1A1TSHRAOC3G6PC1TDP1
SCHEMBL8335334 0.76 ALDH1A1 (0.48) ALDH1A1TSHRAOC3MGLLG6PC1
SCHEMBL3249918 0.73 MGLL (0.45) ALDH1A1TSHRAOC3MGLLCA2
SCHEMBL3239638 0.73 TSHR (0.56) ALDH1A1TSHRAOC3MGLLCA2
SCHEMBL3251335 0.73 AOC3 (0.52) ALDH1A1TSHRAOC3MGLLG6PC1
SCHEMBL7814373 0.72 ALDH1A1 (0.55) ALDH1A1TSHRAOC3MGLLG6PC1
SCHEMBL422733 0.72 ALDH1A1 (0.55) ALDH1A1TSHRAOC3MGLLG6PC1
SCHEMBL3250901 0.71 TSHR (0.45) ALDH1A1TSHRAOC3MGLLG6PC1
SCHEMBL4079504 0.70 ALDH1A1 (0.67) ALDH1A1TSHRAOC3MGLLCA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1167366-B1 AMINE DERIVATIVES DAIICHI SANKYO CO LTD (JP) 2010-05-05 EP disclosed
US-6562849-B1 Amine compound or pharmacologically acceptable salt thereof. These compounds are useful in the treatment and/or prophylaxis of diseases such as diabetes, hyperlipemia, arteriosclerosis, cancer, etc. SANKYO COMPANY, LIMITED (JP) 2003-05-13 US disclosed
US-20030078426-A1 Amine derivative compounds SANKYO COMPANY, LIMITED (JP) 2003-04-24 US disclosed
EP-1167366-A1 AMINE DERIVATIVES Sankyo Company, Limited (JP) 2002-01-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030078426-A1 Amine derivative compounds H1-10, APOB, PRMT1 ALDH1A1 874/4885TSHR 2306/4885AOC3 662/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.